• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

An­ti­bod­ies once act­ed on­ly as pro­tein block­ers. Now, sci­en­tists are find­ing new ways to make them pro­tein de­stroy­ers

8 months ago
Discovery

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

8 months ago
Special

Lab coats and mi­cro­scopes in mar­ket­ing: Does sci­ence still sell in phar­ma ad­ver­tis­ing?

8 months ago
Pharma
Marketing

#ES­MO22: Round­table dis­cus­sion with John Car­roll

8 months ago

Backed by five phar­ma gi­ants and a crew of Penn su­per­stars, a start­up us­es mR­NA to cre­ate in vi­vo CAR-T — with a pro at the helm

8 months ago
Financing
Startups

#ES­MO22: Am­gen drops the de­tailed deck for KRAS G12C, with erod­ing da­ta like­ly to trig­ger fresh de­bate

8 months ago
R&D

#ES­MO22: 'End of the be­gin­ning': As PD-(L)1s press on, how far can com­bo ther­a­pies take im­muno-on­col­o­gy?

8 months ago
R&D
Pharma

#ES­MO22: Am­gen spot­lights con­fir­ma­to­ry win for KRAS G12C play­er Lumakras in lung can­cer — but there's plen­ty more da­ta to come

8 months ago
R&D

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

8 months ago
Pharma
Marketing

Phar­ma's day in court: Is the dai­ly down­pour of law­suits giv­ing phar­ma com­pa­nies a bad rep?

9 months ago
Pharma
Marketing

Chi­na's DNA gi­ant con­fronts skep­ti­cism in US ex­pan­sion bid

9 months ago
China
In Focus

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

9 months ago
R&D
In Focus

Q&A: GSK vac­cine leader Judy Stew­art nav­i­gates vac­ci­na­tion slumps, al­ways-on mar­ket­ing and in­no­vat­ing da­ta tools

9 months ago
Pharma
Marketing

Biotech's 'sug­ar high' led to a cor­rec­tion, but win­ter dol­drums could make way for a turn­around sto­ry this fall

9 months ago
Financing
In Focus

Biotech’s down­turn fu­els a bil­lion­aire’s niche in­vest­ment in­dus­try

9 months ago
R&D
In Focus

ICY­MI: James Sabry just signed off on a land­mark first for Roche's deal­mak­ing crew

9 months ago
Bioregnum
China

Those big bil­lion-dol­lar PhI­II stud­ies? Mar­tin Lan­dray says they can be done for a tiny frac­tion of the cost

9 months ago
R&D
In Focus

Cerev­el's Tony Coles is still count­ing his mon­ey as a ri­val's boost helps fu­el a po­ten­tial $609M wind­fall

9 months ago
Financing
Bioregnum

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

9 months ago
Cell/Gene Tx

'Messy at best': Is the US re­peat­ing the same Covid mis­steps with mon­key­pox mes­sag­ing?

9 months ago
Pharma
Marketing

Why non-opi­oid pain drugs keep fail­ing — and what's next for the field

9 months ago
R&D
In Focus

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

9 months ago
People
Cell/Gene Tx

George Yan­copou­los says he's on the trail of the holy grail: ‘This could rep­re­sent the next break­through for im­munother­a­py’

10 months ago
Bioregnum
Pharma

Gran­flu­encers and boom­flu­encers: Is the hip­ster old­ster so­cial me­dia trend mov­ing to phar­ma?

10 months ago
Pharma
Marketing
First page Previous page 6789101112 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET